Mary Ella Pierpont1,2, Maria Cristina Digilio3. 1. Department of Pediatrics, University of Minnesota. 2. Cardiovascular Research, Children's Hospital of Minnesota, Minneapolis, Minnesota, USA. 3. Medical Genetics, Bambino Gesù Children's Hospital, Rome, Italy.
Abstract
PURPOSE OF REVIEW: To provide information on the scope of cardiac disease in Noonan syndrome. RECENT FINDINGS: Noonan syndrome is a common autosomal dominant RASopathy disorder characterized by clinical findings of facial dysmorphism, congenital heart disease, and short stature. The degree of genetic heterogeneity has recently become evident in that Noonan syndrome is now known to be caused by mutations in a large variety of genes which produce dysregulation of the RAS-MAPK (mitogen-activated protein kinase) signaling pathway. The scope of cardiac disease in Noonan syndrome is quite variable depending on the gene mutation, with some mutations usually associated with a high incidence of congenital heart defects (PTPN11, KRAS, and others) while those with predominantly hypertrophic cardiomyopathy (HCM) have higher risk and morbidity profiles (RAF1, RIT1, and those associated with multiple lentigines). SUMMARY: Cardiac disease in Noonan syndrome varies according to the type of gene mutation. The most common forms of cardiac disease include pulmonary stenosis, HCM, and atrial septal defect. HCM in general is associated with increased risk, mortality, and morbidity. New concepts for potential treatments are discussed.
PURPOSE OF REVIEW: To provide information on the scope of cardiac disease in Noonan syndrome. RECENT FINDINGS:Noonan syndrome is a common autosomal dominant RASopathy disorder characterized by clinical findings of facial dysmorphism, congenital heart disease, and short stature. The degree of genetic heterogeneity has recently become evident in that Noonan syndrome is now known to be caused by mutations in a large variety of genes which produce dysregulation of the RAS-MAPK (mitogen-activated protein kinase) signaling pathway. The scope of cardiac disease in Noonan syndrome is quite variable depending on the gene mutation, with some mutations usually associated with a high incidence of congenital heart defects (PTPN11, KRAS, and others) while those with predominantly hypertrophic cardiomyopathy (HCM) have higher risk and morbidity profiles (RAF1, RIT1, and those associated with multiple lentigines). SUMMARY:Cardiac disease in Noonan syndrome varies according to the type of gene mutation. The most common forms of cardiac disease include pulmonary stenosis, HCM, and atrial septal defect. HCM in general is associated with increased risk, mortality, and morbidity. New concepts for potential treatments are discussed.
Authors: Carolina Putotto; Flaminia Pugnaloni; Marta Unolt; Stella Maiolo; Matteo Trezzi; Maria Cristina Digilio; Annapaola Cirillo; Giuseppe Limongelli; Bruno Marino; Giulio Calcagni; Paolo Versacci Journal: Children (Basel) Date: 2022-05-25
Authors: Rong Li; Amanda Baskfield; Yongshun Lin; Jeanette Beers; Jizhong Zou; Chengyu Liu; Fabrice Jaffré; Amy E Roberts; Elizabeth A Ottinger; Maria I Kontaridis; Wei Zheng Journal: Stem Cell Res Date: 2018-12-26 Impact factor: 2.020
Authors: Geeske M van Woerden; Richelle Senden; Charlotte de Konink; Rossella A Trezza; Anwar Baban; Jennifer A Bassetti; Yolande van Bever; Lynne M Bird; Bregje W van Bon; Alice S Brooks; Qiaoning Guan; Eric W Klee; Carlo Marcelis; Joel M Rosado; Lisa A Schimmenti; Amy R Shikany; Paulien A Terhal; Kathryn Nicole Weaver; Marja W Wessels; Hester van Wieringen; Anna C Hurst; Catherine F Gooch; Katharina Steindl; Pascal Joset; Anita Rauch; Marco Tartaglia; Marcello Niceta; Ype Elgersma; Serwet Demirdas Journal: Hum Mutat Date: 2022-07-29 Impact factor: 4.700